BRAF mutation can be identified in about 45% of the patients with metastatic melanoma. In
these patients, BRAF and MEK inhibitors are able to induce rapid responses and to prolong …

Abstract Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein
kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune checkpoint …

The development of novel treatments that selectively inhibit the RAS-RAF-MAPK pathway
represents a milestone in the history of melanoma treatment. BRAF mutations occur in …

BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients
with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in …

Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if
detected early, however, treatment options for patients with metastatic melanoma are limited …

Mitogen-activated protein kinase (MAPK) pathway has an important role in normal cells and
can be activated under physiological conditions. MAPK pathway activation is a fundamental …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

Malignant melanoma is associated with poor clinical prognosis; however, novel molecular
and immune therapies are now improving patient outcomes. Almost 50% of melanomas …

As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …

The discovery of activating mutations in the serine/threonine (S/T) kinase BRAF followed by
a wave of follow-up research manifested that the MAPK-pathway plays a critical role in …